Takayama K, Ichiki M, Matsumoto T, et al. - Researchers performed a multicenter phase 2 trial examining the efficacy and tolerability of gemcitabine (GEM)-carboplatin (CBDCA) combination for elderly patients with chemotherapy-naive non-small cell lung cancer (NSCLC). Forty-eight patients with chemotherapy-naive performance status 0–1 and with stage IIIB/IV NSCLC were given chemotherapy biweekly (GEM 1,000 mg/m² with CBDCA area under the blood concentration-time curve (AUC) 3 on days 1 and 15 every 4 weeks). Outcomes revealed satisfactory efficacy of GEM-CBDCA combination administered biweekly with mild toxicities in elderly patients with advanced NSCLC. The median PFS was 5.9 months (95% CI, 4.1–6.6), median OS was 13.3 months (95% CI, 8.3–23.5), and 1-year survival was 58%. Grade ≥ 3 hematological toxicities comprised neutropenia (29.2%), thrombocytopenia (4.2%), and anemia (20.8%). Grade ≥ 3 nonhematological toxicities had an incidence of < 5%.